Spastic Cerebral Palsy

1
Pipeline Programs
2
Companies
2
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
1
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

2 companies ranked by most advanced pipeline stage

Verona Pharma
Verona PharmaUK - London
1 program
1
IncobotulinumtoxinA 100 UNT [Xeomin]Phase 21 trial
Active Trials
NCT05340439Unknown30Est. May 2025
LiNA MEDICAL
LiNA MEDICALDenmark - Naerum
1 program
3-Minute Walking Gait and Surface Electromyography AssessmentN/A1 trial
Active Trials
NCT07316985Completed72Est. Oct 2025

Trial Timeline

Clinical trial activity over time

2022
2023
2024
2025
2026
Verona PharmaIncobotulinumtoxinA 100 UNT [Xeomin]
LiNA MEDICAL3-Minute Walking Gait and Surface Electromyography Assessment

Clinical Trials (2)

Total enrollment: 102 patients across 2 trials

NCT05340439Verona PharmaIncobotulinumtoxinA 100 UNT [Xeomin]

INcobotulinumtoxina in ChIldren Upper and Lower Limb sPasticITy (INCIPIT)

Start: Jun 2022Est. completion: May 202530 patients
Phase 2Unknown
NCT07316985LiNA MEDICAL3-Minute Walking Gait and Surface Electromyography Assessment

Time-Dynamic Analysis of Gait Variability in Children With Spastic Cerebral Palsy ( SCP-TIME )

Start: Jun 2024Est. completion: Oct 202572 patients
N/ACompleted

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

2 companies competing in this space